Skip to main content

Table 4 Summary of reproductive performance in females treated with ProHeart® 12 at 1.5 mg/kg (3× overdose)

From: Safety of an extended-release injectable moxidectin suspension formulation (ProHeart® 12) in dogs

Timing of treatment

None (Control)

Pre-Mating

Mating

Mid-gestation

Lactation

Pups per Litter (mean ± SD)

4.3 ± 2.12

5.5 ± 1.85

5.0 ± 1.77

6.1 ± 2.34

6.3 ± 1.96

Liveborn/Total (%)

100

100

100

100

100

Postnatal viabilitya (% ± SD)

92 ± 17.68

97.9 ± 5.89

100 ± 0.00

93.3 ± 8.64

100 ± 0.00

Birth weight (g) (mean ± SD)

 Males

308 ± 31.6

300 ± 47.62

290 ± 50.91

275 ± 35.40

309 ± 55.46

 Females

292 ± 26.30

266 ± 72.34

270 ± 27.98

269 ± 22.29

295 ± 39.90

Weaning weight (g) (mean ± SD)

 Males

2288 ± 134.7

2172 ± 242.8

2170 ± 252.9

2060 ± 172.2

2174 ± 503.9

 Females

1996 ± 221.7

1912 ± 310.4

2038 ± 394.0

1914 ± 282.3

1865 ± 330.1

  1. Note: No statistical differences were identified in any indices of reproductive performance (P > 0.05)
  2. aNumber liveborn that were weaned on Day 42
  3. Abbreviation: SD, standard deviation